E-Mail
IMAGE: A new review has found China has made remarkable gains in reducing the number of women who die during childbirth and boosting child survival rates over the past 70 years. view more
Credit: Rui Xu
China has made remarkable gains in reducing the number of women who die during childbirth and boosting child survival rates over the past 70 years, according to new review.
The Lancet report brought together China s health research institutions alongside its international colleagues from Australia, the UK and the US to review the country s progress in maternal, newborn, child and adolescent health and nutrition since 1949.
Murdoch Children s Research Institute (MCRI) Professor George Patton, one of the international researchers, said over the past 70 years China had made a remarkable transition from where the survival of women and children was the priority to one where children and adolescents now have similar health profiles to young Australians.
Low efficacy of Chinese vaccines sows concern over global rollout
China’s COVID-19 vaccines, administered in large parts of the developing world,
are not even trusted by the country’s own health officials, a researcher said
Bloomberg
Concern is mounting that China’s COVID-19 vaccines are less effective at quelling the disease, raising questions about nations from Brazil to Hungary that are depending on the shots and Beijing’s own mammoth inoculation drive.
While vaccines developed by Pfizer and Moderna, and even Russia’s Sputnik shot, have delivered protection rates of more than 90 percent, Chinese candidates have generally reported much lower efficacy results.
BEIJING (BLOOMBERG) - Concern is mounting that China s Covid-19 vaccines are less effective at quelling the disease, raising questions about nations from Brazil to Hungary that are depending on the shots and the country s own mammoth inoculation drive.
While vaccines developed by Pfizer, Moderna and even Russia s Sputnik have delivered protection rates of more than 90 per cent, Chinese candidates have generally reported much lower efficacy results.
Research released on Sunday showed that the rate for Sinovac Biotech s vaccine - deployed in Indonesia and Brazil - was just above 50 per cent, barely meeting the minimum protection required for Covid-19 vaccines by leading global drug regulators.
. Concern is mounting that China s coronavirus vaccines are less effective at quelling the disease, raising questions about nations from Brazil to Hungary that are depending on the shots and the country s own mammoth inoculation drive. While vaccines developed by Pfizer Inc., Moderna Inc. and even Russia s Sputnik shot have delivered protection rates of more than 90%, Chinese candidates have generally reported much lower efficacy results. Research released Sunday showed the rate for Sinovac Biotech Ltd. s vaccine deployed in Indonesia and Brazil was just above 50%, barely meeting the minimum protection required for coronavirus vaccines by leading global drug regulators. The other Chinese shots have reported efficacy rates of between 66% to 79%.
news
Closer cooperation needed as global COVID-19 cases top 100 mln Jiang Chao,Yang Yi,Li Binian,Yang Yiran,unreguser,Shui Jinchen,Qu Yan,Liu Meizi,Ji Xiaozhuang,Yu Guoqing,Pan Zhiwei,Yue Wenwan,Li Aibin,Zhang Mocheng,Xie E
Closer cooperation needed as global COVID-19 cases top 100 mln
Replay Video UP NEXT
NEW YORK, Jan. 27 (Xinhua) Global COVID-19 cases surpassed 100 million on Tuesday, according to the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University.
The global case count reached 100,032,461, with a total of 2,149,818 deaths worldwide, as of 2:22 p.m. local time (1922 GMT), the CSSE data showed.